Mild Traumatic Brain Injury (mTBI), commonly known as concussion is the most common brain injury, inflicting a tremendous cost burden on the healthcare system, estimated at approximately $17 Billion annually in the US alone.
One of the common causes for concussion is sports related injury. Sport-Related Concussion (SRC) affects as many as 3.8 million people in the US alone. The injury is often not directly visible, and early mTBI symptoms may appear mild, but they can lead to significant, life-long impairment in an individual’s ability to function physically, cognitively, and psychologically. It is therefore highly important that SRC is promptly assessed and managed to prevent further complications.
Given the great variability in symptoms and presentations, the clinical diagnosis of concussion is particularly difficult, and represents a significant challenge for sports medicine providers. Moreover, once a concussion is diagnosed, determining when the patient is clear to return to full activity represents an even bigger challenge for clinicians, since it is well known today that symptoms resolution alone does not necessarily reflect complete recovery. Despite ongoing research, there is no single, direct, objective and sensitive test available for concussion management. Current recommendations are that sports medicine providers apply a multifaceted concussion assessment battery that combines subjective symptoms, motor control (e.g., postural stability), and cognitive assessment. Neuroimaging techniques play only a limited role in concussion assessment, either due to the functional (i.e. non-structural) nature of the injury (in the case of CT, MRI, DTI) or as a result of their cost and availability.
ElMindA has successfully completed a proof of concept for the utility of BNA™ technology in concussion management. The company’s BNA™ platform for concussion has attracted some of the top research centers for traumatic brain injury in the U.S. to serve as clinical sites for the advancement of the technology in this area.